[Gastrointestinal cancer].
Ten patients with refractory gastrointestinal cancer received nonmyeloablative allogeneic stem-cell transplantation(NST) from HLA-identical sibling. The conditioning regimen consisted of cyclophosphamide and fludarabine. None of the patients rejected the allograft. Five patients developed grade II-III acute GVHD and 5 patients developed extensive chronic GVHD. Three patients achieved remarkable serum tumor marker regressions after the steroids were discontinued, which were attributed to graft-versus-tumor (GVT) effects. One patient achieved a partial response, and three patients had stable disease. At a median follow up of 155.5 days (52-349), 2 patients are alive and 8 patients died for progressive disease. NST for refractory gastrointestinal cancer was feasible. Although GVT effects against gastrointestinal cancer were observed, the effects were limited for highly progressive disease.
D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000628:therapy*; D006086:Graft vs Host Disease / Q000209:etiology; D020350:Graft vs Tumor Effect; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000009:adverse effects; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine